Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
03:53pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity
01:52am, Tuesday, 13'th Jan 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $16.08,
Leon Moulder, Jr. Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
05:28am, Sunday, 11'th Jan 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 20,000 shares of the business's stock in a transaction on Friday, January 9th. The shares were acquired at an ave
Leon Moulder, Jr. Acquires 30,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
05:28am, Sunday, 11'th Jan 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 30,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was bought at an av
Leon Moulder, Jr. Acquires 50,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
04:40am, Sunday, 11'th Jan 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 50,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were bought at an average c
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
09:01am, Saturday, 10'th Jan 2026
The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
10:16pm, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to c
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to c
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
02:58pm, Tuesday, 06'th Jan 2026
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
12:50pm, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
12:21pm, Tuesday, 06'th Jan 2026
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Why Zenas BioPharma's Selloff Was Structurally Inevitable
07:38am, Tuesday, 06'th Jan 2026
Zenas BioPharma (NASDAQ: ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor
04:58am, Tuesday, 06'th Jan 2026
Zenas BioPharma remains a 'Strong Buy' after Obexelimab met the phase 3 INDIGO primary endpoint in IgG4-RD, despite a sharp stock decline. The company's pipeline is advancing with Orelabrutinib, a p
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56%
04:32am, Tuesday, 06'th Jan 2026
Zenas BioPharma (NASDAQ: ZBIO) reported top-line results from its registrational phase III INDIGO trial evaluating obexelimab for immunoglobulin G4-related disease (IgG4-RD), saying the study met its
